Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
A definitive Manual for Internet Mastering and Expertise Improvement - 2Trump administration plan to reduce access to some student loans angers nurses, health care groups
- 3Feeling wonder every day improves our health. Here’s how to do it.
- 4Make your choice for the PS5 game that you love playing with companions!
- 5Novo Nordisk slashes prices of popular weight loss and diabetes drugs
- Could the Star of Bethlehem have actually been a comet?
- ISS astronaut snaps stunning nighttime photo of Florida and Cuba | Space photo of the day for Dec. 29, 2025
- How stripping diversity, equity and inclusion from health care may make Americans sicker
- Becoming amazing at Arranging Pay Raises
- Trial of pro-Palestine activist begins
- She's been a Bond girl and a mutant. Now she's grappling with Hollywood's obsession with 'eternal youth.'
- Get away from the Tedious Drudgery: Go into Business Today!
- New dinosaur tracks in Italy illustrate herds moving in unison
- Eating Brie, Gouda, cheddar may lower dementia risk, new study says
